Table 1.
Pharmaceutical based therapeutics for Lassa virus (LASV) in non-human primates (NHP) models.
| Animal Model | Challenge | Treatment Regimen | Survival | Reference |
|---|---|---|---|---|
| Ribavirin | ||||
| Rhesus Macaque |
SQ 10,000 PFU LASV | (1) Loading dose 50 mg/kg 0 dpi + 10 mg/kg three times daily to day 18 IM (N = 4) | (1) 100% | [50] |
| (2) Loading dose 5 dpi + 10 mg/kg three times daily to day 18 IM (N = 4) | (2) 100% | |||
| (3) Controls (N = 10) | (3) 60% | |||
| Rhesus Macaque |
SQ 1.2 × 106 PFU LASV Josiah | (1) Loading dose 50 mg/kg 0 dpi + 10 mg/kg three times daily to day 18 SQ (N = 4) | (1) 100% | [51] |
| (2) Loading dose 50 mg/kg 5 dpi + 10 mg/kg three times daily to day 18 SQ (N = 4) | (2) 100% | |||
| (3) Controls (N = 1(0) | (3) 60% | |||
| Cynomolgus Macaque | SQ 1.2 × 106 PFU LASV Josiah | (1) Loading dose 150 mg/kg 0 dpi + 15 mg/kg twice daily to day 18 IM (N = 4) | (1) 100% | [52] |
| (2) Loading dose 150 mg/kg 4 dpi + 15 mg/kg twice daily to day 18 IM (N = 4) | (2) 100% | |||
| (3) Loading dose 150 mg/kg 7 dpi + 15 mg/kg twice daily to day 18 IM (N = 8) | (3) 50% | |||
| (4) Loading dose 300 mg/kg 7 dpi + 30 mg/kg twice daily to day 18 IM (N = 4) | (4) 25% | |||
| (5) Loading dose 450 mg/kg 7 dpi + 45 mg/kg twice daily to day 18 IM (N = 6) | (5) 0% | |||
| (6) Untreated controls (N = 1(4) | (6) 0% | |||
| Cynomolgus Macaque | IM 1 × 104 TCID50 LASV Josiah | (1) 30 mg/kg loading dose 4 dpi + 10 mg/kg every 8 h SQ (N = 4) | (1) 0% | [53,54] |
| (2) 30 mg/kg loading dose + 30 mg/kg once daily SQ | (2) 0% | |||
| (3) Placebo controls | (3) 0% | |||
| Favipiravir | ||||
| Cynomolgus Macaque | IM 1 × 104 TCID50 LASV Josiah | (1) 300 mg/kg IV loading dose 4 dpi + 300 mg/kg per day SQ treatments for 13 more days (N = 4) | (1) 100% | [53,54] |
| (2) Placebo treated starting 4 dpi to death (N = 4) | (2) 0% | |||
| Cynomolgus Macaque | IM 1 × 104 TCID50 LASV Josiah | (1) 300 mg/kg IV loading dose 4 dpi + 50 mg/kg every 8 h SQ treatments for 13 more days (N = 4) | (1) 0% | [53,54] |
| (2) Placebo treated 4 dpi to death (N = 8) | (2) 0% | |||
IM = intramuscular. SQ = subcutaneous. DPI = days post infection. N = group size. PFU = plaque forming units. FFU = fluorescent focus units. GPA = guinea pig adapted. LASV = Lassa virus.